SLC5A2 and Hypoglycemia: Given the potential risk of hypovolemia, hypoglycemia, and DKA, a “sick day protocol” can be implemented where pausing SGLT2 inhibitor treatment is considered during acute illness, vomiting, diarrhea, and inability to eat or drink (4).